Search company, investor...
HiLife Vitamins company logo

HiLife Vitamins

Founded Year


About HiLife Vitamins

HiLife Vitamins operates as a retail and online proprietor of vitamin supplements. The products include amino acids, antioxidants, and biotin supplements, and herb-based supplement products. HiLife Vitamins was founded in 1971 and is based in Chatham, New Jersey.

Headquarters Location

48 River Road

Chatham, New Jersey, 07928,

United States

Missing: HiLife Vitamins's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: HiLife Vitamins's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

HiLife Vitamins Frequently Asked Questions (FAQ)

  • When was HiLife Vitamins founded?

    HiLife Vitamins was founded in 1971.

  • Where is HiLife Vitamins's headquarters?

    HiLife Vitamins's headquarters is located at 48 River Road, Chatham.

  • Who are HiLife Vitamins's competitors?

    Competitors of HiLife Vitamins include LemonBox and 4 more.

Compare HiLife Vitamins to Competitors


Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.

Everist Health Logo
Everist Health

Everist Health (formerly Everist Genomics and Genetics Squared) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Through their tools, the company seeks to help physicians improve medical outcomes and reduce the total cost of care. EGI's products integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology.

Seaside Therapeutics

Seaside Therapeutics is creating new drug treatments to correct or improve the course of Fragile X Syndrome, autism and other disorders of brain development.


Bionas specializes in analyzing systems for in vitro profiling the metabolic activity of cells with special respect to cellular bioenergetics, adhesion and morphology.

Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.